NUEVO TRABAJO SOBRE EL RIMONABANT (SERENADE)

Nuevo trabajo sobre el Rimonabant en diabéticos (SERENADE) presentado en Ciudad del Cabo
SERENADE was a multicenter, randomized, placebo-controlled study comparing rimonabant 20 mg once daily with placebo in improving blood-sugar control in treatment-naive type 2 diabetics not adequately controlled by diet alone for a period of six months. There were 278 patients enrolled at 56 study centers in the US, Germany, Argentina, Chile, Hungary, Poland, and the Netherlands
At baseline, both the placebo and active-treatment groups had HbA1c levels of 7.9%, and by the end of six months of treatment, those receiving rimonabant had a significant 0.8% lowering of HbA1c from baseline, compared with 0.3% in the placebo group (p=0.002). In addition, those with levels of HbA1c of 8.5% or greater at baseline had "very robust" reductions of HbA1c with rimonabant, Rosenstock said--1.9% vs 0.7% with placebo (p<0.0009). These effects on HbA1c were accompanied by significant improvements in a range of other cardiometabolic risk factors, with the exception of blood pressure.
Approximately 57% of the improvements in HbA1c were independent of the weight loss achieved